UiPath plunges after Q4 results, but Needham upgrades to Buy on new ARR

UiPath (PATH) stock slides after Q4 FY26 results as Needham upgrades to Buy on ARR and free cash flow growth; AI ARR hits $200M.
Hosted on MSN

How UiPath (PATH) is using agentic AI to tackle healthcare payment bottlenecks

UiPath, Inc. (NYSE:PATH) is one of the cheap AI stocks to buy in 2026. On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting ...
Yahoo Finance

How The UiPath (PATH) Story Is Shifting As Analyst Targets And Fair Value Converge

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. UiPath’s blended fair value estimate has been trimmed from US$16.19 to US$15.93, a ...
Yahoo Finance

UiPath Expands Into Healthcare AI As Valuation Lags Analyst Targets

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. UiPath (NYSE:PATH) has launched agentic AI automation tools tailored for healthcare ...